Xenotransplantation reached a pivotal milestone after the FDA approved the first official human clinical trials for genetically modified pig kidneys in early 2025. The trials follow several breakthrough compassionate-use cases, including a historic April 2024 operation at NYU Langone where surgeons successfully combined a mechanical heart pump with a gene-edited pig kidney and thymus gland in a single patient.
The donor pigs undergo multi-gene editing to prevent acute organ rejection and are raised in pathogen-free facilities. More than 11 xenotransplants have been performed on living human recipients across the United States since 2022.
While recipient survival outcomes have varied, the initiation of structured clinical trials aims to establish standardized safety parameters. With over 90,000 Americans currently on the kidney waitlist, scalable xenotransplantation could potentially alleviate the chronic global organ shortage.
Comments
Post a Comment